en
/
sv
About Elicera
Elicera in brief
Board
Team
Advisors
Elicera's history
Immuno-oncology
What is immuno-oncology?
CAR T-cell therapy
Oncolytic virus
Technology
CAR T-cell therapy
Challenges
Mode-of-action
Scientific publications
Pipeline
Pipeline
ELC-301
ELC-401
ELC-201
ELC-100
Clinical trials
Patent portfolio
Investors
Press Releases
Corporate Governance
the Share
Financial Reports
Financial Calendar
Events
Share issues
Analyst Coverage
News
News
Press Releases
Events
Contact
en
/
sv
Financial Reports
2024
Q2 report 2024
pdf
Q1 report 2024
pdf
2023
Annual report 2023
pdf
Year-end report 2023
pdf
Q3 report 2023
pdf
Q2 report 2023
pdf
Q1 report 2023
pdf
2022
Annual Report 2022
pdf
Q4 report 2022
pdf
Q3 report 2022
pdf
Q2 report 2022
pdf
Q1 report 2022
pdf
2021
Annual report 2021
pdf
Year-end report 2021
pdf
Q3-report Elicera 2021
pdf
Q2-report 2021
pdf
Q1-report 2021
pdf
2020
Annual Report 2020
pdf
Year-end report 2020 (Swe)
pdf
2015-2019
Q2 report 2024
pdf
Q1 report 2024
pdf
Annual report 2023
pdf
Year-end report 2023
pdf
Q3 report 2023
pdf
Q2 report 2023
pdf
Q1 report 2023
pdf
Annual Report 2019 (Swe)
pdf
Annual Report 2018 (Swe)
pdf
Annual Report 2017 (Swe)
pdf
Annual Report 2016 (Swe)
pdf
Annual Report 2015 (Swe)
pdf
By continuing to browse this website you agree to cookies being stored on your device in order to improve the experience and analyze how it is being used. Read more in our
Integrity policy
.
Deny
Accept